Iris L. van Staveren

Author

Rotterdam University of Applied Sciences

Also Known As

I L van Staveren, I. L. van Staveren, I.L. van Staveren, Iris L van Staveren, Iris L. Van Staveren, Iris L. van Staveren

Publications

2.4K

Citations

H-Index

Concepts

All Affiliations

Rotterdam University of Applied Sciences Erasmus University Rotterdam Erasmus MC Erasmus MC Cancer Institute Meertens Institute

About

Iris L. van Staveren is an author at Rotterdam University of Applied Sciences specializing in medicine, breast cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	14	1.3K
2	Cell Biology	5	5	394
3	Engineering	1	1	162
4	Health Sciences	1	1	17
5	Molecular Biology	1	1	162

Iris L. van Staveren

Publications

2.3K

Citations

H-Index

Page 1

	Year	Citations
Molecular Classification of Tamoxifen-Resistant Breast Carcinomas by Gene Expression Profiling Maurice P.H.M. Jansen, John A. Foekens, Iris L. van Staveren, Journal of Clinical Oncology	2005	331
c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. E. Berns, J.G.M. Klijn, W L van Putten, PubMed Her2/neu GenesBreast OncologyMedicineHer2/neu AmplificationPathology	1992	206
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. E. Berns, John A. Foekens, R. van Vossen, PubMed Breast OncologyPathologyComplete SequencingSystemic TherapyCancer Biology	2000	197
Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment Els M.J.J. Berns, John A. Foekens, Iris L. van Staveren, Gene Oncogene AmplificationBreast OncologyOncogenic AgentMedicineSystemic Treatment	1995	175
Association of an Extracellular Matrix Gene Cluster with Breast Cancer Prognosis and Endocrine Therapy Response Jozien Helleman, Maurice P.H.M. Jansen, Kirsten Ruigrok-Ritstier, Clinical Cancer Research	2008	171
Molecular profiling of platinum resistant ovarian cancer Jozien Helleman, Maurice P.H.M. Jansen, Paul N. Span, International Journal of Cancer Platinum ResistanceEngineeringGene SignatureTumor HeterogeneityMedicine	2005	162
<i>HOXB13</i>-to-<i>IL17BR</i> Expression Ratio Is Related With Tumor Aggressiveness and Response to Tamoxifen of Recurrent Breast Cancer: A Retrospective Study Maurice P.H.M. Jansen, Anieta M. Sieuwerts, Maxime P. Look, Journal of Clinical Oncology	2007	127
Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: Correlation with steroid receptors Els M.J.J. Berns, Jan G.M. Klijn, Iris L. van Staveren, European Journal of Cancer Breast OncologyOncogenes C-mycOncogenic AgentMedicineSteroid Receptors	1992	121
Mismatch repair and treatment resistance in ovarian cancer Jozien Helleman, Iris L. van Staveren, Winand N.M. Dinjens, BMC Cancer	2006	94
Sporadic amplification of the insulin-like growth factor 1 receptor gene in human breast tumors. E. Berns, J.G.M. Klijn, Iris L. van Staveren, PubMed Human Breast TumorsBreast OncologyC-myc GenePathologyCancer Biology	1992	85

Page 1